Published on
December 22, 2023
- 09:30 GMT
Zealand Pharma submits New Drug Application to the US FDA for glepaglutide in short bowel syndrome
Press release – No. 18 / 2023 Zealand Pharma submits New Drug Application to the US FDA for glepaglutide in short bowel syndrome Copenhagen, Denmark, December 22, 2023 – Zealand Pharma A/S (Nasdaq: ZEAL) (“Zealand”) (CVR-no. 20045078), a biotechnology …
Distribution channels:
Healthcare & Pharmaceuticals Industry
...
